Clinical Trials Logo

Filter by:
NCT ID: NCT03620591 Completed - Postoperative Pain Clinical Trials

Lidocaine and Analgesia After Laparoscopic Cholecystectomy

Start date: July 2, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate how effective is the intraoperative use of lidocaine to attenuate postoperative pain and opioids consumption after laparoscopic cholecystectomy

NCT ID: NCT03618394 Completed - Clinical trials for Bone Turnover Rate Disorder

Bone Turnover and Parenteral Nutrition

Start date: April 1, 2015
Phase:
Study type: Observational

Evaluation of changes in biochemical markers of bone metabolism. Fat profile. Evaluation of the overall body development. Assessment of parenteral nutrition protocols.

NCT ID: NCT03612817 Completed - Clinical trials for Glaucoma, Open-Angle

Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing

TTFC
Start date: January 2017
Phase: Phase 4
Study type: Interventional

The ideal dosing for preservative-free tafluprost/timolol fixed combination remains to be elucidated. The present study compared the 24-hour intraocular pressure efficacy obtained with tafluprost/timolol given once in the evening with placebo once in the morning, versus that with the same fixed combination administered once in the morning with placebo given once in the evening in consecutive patients with open-angle glaucoma insufficiently controlled with branded, or generic latanoprost monotherapy.

NCT ID: NCT03609437 Completed - Clinical trials for Endothelial Dysfunction

Impaired Endothelial Integrity in Patients With Embolic Stroke of Undetermined Source (ESUS)

ESUS
Start date: January 1, 2018
Phase:
Study type: Observational

Cardioembolism is a postulated mechanism of an embolic stroke of undetermined source (ESUS). The investigators will measure endothelial glycocalyx, aortic elastic properties, oxidative stress, and their association with left ventricular (LV) and left atrial (LA) function in ESUS and age- and sex-adjusted healthy individuals.

NCT ID: NCT03602560 Completed - Clinical trials for Primary Biliary Cholangitis

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Start date: October 1, 2018
Phase: Phase 3
Study type: Interventional

A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA) The participants might enter the ongoing open-label safety study (NCT03301506) following this double-blind study.

NCT ID: NCT03602248 Completed - Control Clinical Trials

Speed Endurance Training, Muscle Damage and Performance in Soccer Players

SPENSER
Start date: May 8, 2018
Phase: N/A
Study type: Interventional

Soccer is an intermittent sport in which the aerobic and anaerobic capacity of the players are both very important. Elite football players perform an average of 150-250 short and intense movements during a match, demonstrating the significant contribution of the anaerobic energy system. Speed endurance training consists a tool to enhance the performance of aerobic and anaerobic system. This training includes actions such as sprinting, changes of direction, accelerations, decelerations, jumps and shooting, characterized by a strong eccentric component. Eccentric actions are associated with exercise induced muscle damage (EIMD). Nevertheless, to date, EIMD responses following a session of speed endurance training have not yet been investigated. Therefore, the aim of the present study is to examine the EIMD responses and changes on performance and neuromuscular fatigue indices after two different speed endurance training protocols.

NCT ID: NCT03597828 Completed - Clinical trials for Pleural Effusion, Malignant

Respiratory Function of Dexmedetomidine in Patients Undergoing Pleuroscopy

Start date: August 5, 2018
Phase:
Study type: Observational

The primary objective of this prospective trial will be to assess the effects of dexmedetomidine administration on oxygenation and respiratory function in patients undergoing diagnostic or therapeutic medical thoracoscopy/pleuroscopy for a pleural effusion compared to conventional conscious sedation/monitored anesthesia care (MAC) with midazolam. The secondary endpoint of the study will be to also assess the effects of dexmedetomidine administration on respiratory mechanics and postprocedural complications

NCT ID: NCT03597074 Completed - Sepsis Clinical Trials

Doppler Ultrasound for Prediction of Reversibility of Acute Kidney Injury in Septic ICU Patients

Start date: March 2, 2017
Phase:
Study type: Observational

Purpose: The aim of this study was to assess the ability of early discrimination between transient and persistent Acute Kidney Injury (AKI) using the color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization in septic patients in an Intensive Care Unit (ICU). Methods: Prospective observational cohort study with unselected, with 32 adult consecutive septic patients. Patients were divided into 3 groups: Group 1: patients without progression to AKI, Group 2: transient AKI, Group 3: persistent AKI.

NCT ID: NCT03595553 Completed - Clinical trials for Clostridioides Difficile Infection

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

Ri-CoDIFy 1
Start date: January 28, 2019
Phase: Phase 3
Study type: Interventional

Summit is developing ridinilazole as a novel antimicrobial for Clostridioides difficile Infection (CDI), formerly known as Clostridium difficile Infection, with the goal of demonstrating an improved Sustained Clinical Response rate in subjects treated with ridinilazole as compared to subjects treated with vancomycin. A phase 2 proof of concept study, with vancomycin as comparator, demonstrated these attributes with a comparable safety profile. A high fecal concentration of ridinilazole and little systemic exposure were noted. The rationale for this phase 3 study is to confirm the improvement in sustained clinical response of CDI over vancomycin and to compare the safety and tolerability of ridinilazole to that of vancomycin. Ridinilazole plasma concentration will be assessed in a subset of patients.

NCT ID: NCT03592069 Completed - H.Pylori Infection Clinical Trials

Concomitant Versus Hybrid Regimen for H. Pylori Eradication

Start date: February 21, 2018
Phase: Phase 4
Study type: Interventional

10 day concomitant versus 14 day hybrid regimen as first line H. pylori eradication treatment in a high clarithromycin resistance area. A multicenter, randomized, equivalence trial.